Skip to main content

Table 1 Characteristics of the included clinical trials in this study

From: Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis

Study

Location

Study

design

Sample size

(n)

Sex (M/F)

(n)

Age (yrs)

HBeAg(+)/(-)

(n)

LAM-resistance mutations at baseline

(LAM+ADV) / ETV (n)

Regimen

Therapy period

LAM+ADV

vs. ETV

Baseline ALT

(IU/L)

LAM+ADV

vs. ETV

HBVDNA level

LAM+ADV vs. ETV

The detection limit

of HBV DNA

   

LAM

+ADV

ETV

LAM

+ADV

ETV

LAM+ADV

vs . ETV

LAM

+ADV

ETV

 

LAM+ADV

ETV

    

Pellicelli 2009

Italy

RCTs

20

42

NA

NA

Mean (SD):

47 (11)

vs. 48 (9)

NA (NS)

 

NA

LAM 100 mg/d +

ADV 10 mg/d

1.0 mg/d

48 weeks

vs. 48 weeks

NA

Mean (SD) (log10 IU/ml):

5 (1.0) vs. 4.63 (1.3)

NA

Qiu

2009

China

RCTs

30

30

NA

NA

NA

15/15

16/14

NA

LAM 100 mg/d +

ADV 10 mg/d

1.0 mg/d

48 weeks

vs. 48 weeks

Mean (SD):

141.1 (58.2)

vs. 145.7 (61.9)

Mean (SD) (log10 copies/ml):

7.78 (2.62) vs.7.82 (2.32)

< 500 copies/ml

Ryu

2010

Korea

RCTs

47

45

34/13

38/7

Median (rang):

47 (20-68)

vs. 41 (21-60)

39/8

42/3

M204I:14/15; L180M:1/0;

M204I+M204V:0/1; M204I+L180M:8/9

M204V+L180M:14/13

M204I+M204V+L180M:10/7

LAM 100 mg/d +

ADV 10 mg/d

1.0 mg/d

Median (rang), months:

12 (12-24)

vs. 15 (12-27)

Median (range):

143 (26-1096)

vs. 102 (17-677)

Median (rang) (log10 copies/ml):

7.61 (5.19-9.46) vs.7.10 (5.43-9.47)

< 300 copies/ml

Kim

2010

Korea

Cohort

36

24

25/11

21/3

Mean (SD):

46.8 (10.4)

vs. 46.9 (8.7)

20/16

18/6

M204I or M204I+L180M: 24/11

M204V+L180M: 12/13

LAM 100 mg/d +

ADV 10 mg/d

1.0 mg/d

24 months

vs.24 months

Mean (SD):

227.6 (267.8)

vs. 136.3 (134.2)

Mean (SD) (log10 copies/ml):

6.43 (1.40) vs. 6.51 (1.54)

< 300 copies/ml

Lee

2010

Korea

Cohort

48

33

NA (NS)

NA

(NS)

NA (NS)

41/7

30/3

NA

LAM 100 mg/d +

ADV 10 mg/d

1.0 mg/d

96 weeks

vs. 96 weeks

NA (NS)

NA (NS)

< 140 copies/ml

Chung 2011

Korea

Cohort

44

52

35/9

33/19

Mean (SD):

53.7 (10.5)

vs. 50.0 (10.4)

26/18

33/19

M204V+ L180M: 18/21

M204I+ L180M: 9/9

M204V/I+ L180M: 2/5

M204I: 14/17

M204V/I+ L180M+ V173L: 1/0

LAM 100 mg/d +

ADV 10 mg/d

1.0 mg/d

48 weeks

vs. 48 weeks

Mean (SD):

151 (125)

vs. 193 (185)

Mean (SD) (log10 IU/ml):

6.86 (1.17) vs. 6.81 (1.03)

< 50 IU/ml

  1. NA: not available; NS: not significant; iLAM: lamivudine; ADV: adefovir; ETV: entecavir; SD: Standard Deviation; RCTs: randomized controlled trials.